Table 3.
Characteristics of the elaboration set, first 100 patients, and the validation set, remaining 55 patients.
| Characteristics | Elaboration group (n = 100) | Validation group (n = 55) | p |
|---|---|---|---|
| Age, years† | 62 (51–71) | 60 (46–67) | 0.186 |
| Female sex, n (%) | 61 (61) | 36 (66) | 0.583 |
| BMI, Kg/m2† | 28 (26–32) | 28 (25–31) | 0.893 |
| T2DM, n (%) | 18 (18) | 12 (22) | 0.565 |
| Glycemia, mg/dL† | 95 (87–107) | 96 (89–108) | 0.731 |
| HOMA† | 2.4 (1.5–4.1) | 3.0 (1.6–3.7) | 0.607 |
| Triglycerides, mg/dL† | 105 (80–150) | 116 (79–141) | 0.722 |
| Cholesterol, mg/dL† | 193 (172–219) | 191 (174–214) | 0.659 |
| HDL-cholesterol, mg/dL† | 51 (42–61) | 51 (42–58) | 0.547 |
| Metabolic syndrome, n (%) | 68 (68) | 35 (64) | 0.582 |
| ALT, UI/mL† | 18 (14–27) | 17 (15–24) | 0.659 |
| AST, UI/mL† | 19 (16–23) | 18 (15–24) | 0.337 |
| GGT, UI/mL† | 33 (22–65) | 31 (18–53) | 0.283 |
| Liver stiffness, kPa† | 5.2 (4.2–6.4) | 4.8 (3.8–7.2) | 0.355 |
| CAP, dB/m† | 267 (233–322) | 258 (232–301) | 0.353 |
| SAF score, n (%) | |||
| No NAFLD | 52 (52) | 31 (56) | 0.612 |
| NAFLD without NASH | 31 (31) | 13 (24) | |
| NASH | 17 (17) | 11 (20) | |
BMI Body mass index, T2DM type 2 diabetes mellitus, HOMA homeostasis model assessment.
†Median (Q1-Q3).